Ventana Medical Systems | Date: 2016-10-28
A process for removing hematoxylin precipitate from a surface of an automated hematoxylin stainer, systems adapted for performing such processes. The process and systems use a hematein precipitate removal solution having a pH in the range of between about 8.9 and 10.5 and including a liquid oxidizing component and alkaline component. The hematein precipitate removal solution is placed in contact with a surface of the automated hematoxylin stainer, thereby dissolving any hematein precipitate deposited thereon.
Ventana Medical Systems | Date: 2016-08-24
Disclosed herein are novel quinone methide analog precursors and embodiments of a method and a kit of using the same for detecting one or more targets in a biological sample. The method of detection comprises contacting the sample with a detection probe, then contacting the sample with a labeling conjugate that comprises an enzyme. The enzyme interacts with a quinone methide analog precursor comprising a detectable label, forming a reactive quinone methide analog, which binds to the biological sample proximally to or directly on the target. The detectable label is then detected. In some embodiments, multiple targets can be detected by multiple quinone methide analog precursors interacting with different enzymes without the need for an enzyme deactivation step.
Ventana Medical Systems, The Regents Of The University Of California and Hoffmann-La Roche | Date: 2016-08-16
Provided herein are methods of analyzing stage II colorectal cancer (CRC) samples (such as those that are mis-match repair proficient, pMMR), by scoring G-alpha interacting vesicle associated protein (GIV, also known as girdin) full-length (GIV-fl) expression in combination with lymphovascular invasion (LVI) status or clinical variables. The disclosed methods can be used to identify GIV-fl expressing tumors that are likely to recur (high risk) and those that are not likely to recur (high risk). Subjects identified as having a high risk CRC can be selected to receive chemotherapy or biotherapy for the CRC. Thus, in some examples, the disclosed methods can be used to identify CRC tumors that are likely to respond to chemotherapy or biotherapy. Also provided are computer implemented methods, systems, and kits that can be used with these methods.
Ventana Medical Systems | Date: 2016-10-17
An embodiment of the method of the invention is a method of automating information flow in a laboratory performing tissue staining comprising positioning a networked label printer adjacent to a cutting station, the printer configured to access patient data directly or indirectly from the hospital LIS, the printer being configured with a data element scanner in electronic communication with said printer; inputting data from a tissue cassette-associated data element at said printer, whereby inputting data comprises reading the data from the cassette-associated data element and uploading the cassette data to the LIS; identifying the corresponding test protocol identifier and then downloading the test protocol data to the printer; printing information on labels corresponding to each test specified in the LIS for the patient; attaching a single label to each slide; and cutting a tissue section for each labeled slide and mounting the section on the slide.
Ventana Medical Systems | Date: 2016-12-06
Disclosed herein are methods for predicting the response to a HER2-directed therapy and for scoring a breast cancer tumor sample. In some embodiments, the methods include contacting the sample with an antibody that specifically binds HER2 protein and detecting presence and/or amount of HER2 protein and contacting the sample with a nucleic acid probe that specifically binds to HER2 genomic DNA and detecting presence and/or amount of HER2 genomic DNA (such as HER2 gene copy number). In some embodiments, the methods further include detection of a centromere nucleic acid (such as chromosome 17 centromere DNA) and contacting the sample with an antibody that specifically binds ER protein and detecting presence and/or amount of ER protein in the same sample.
Ventana Medical Systems | Date: 2016-03-31
The present invention provides probes and probe systems for detection of nucleic acids, and in particular probes and probe systems comprising target nucleic acid probes which comprise a plurality of detection sequences and detection nucleic acid probes which hybridize to the detection sequences of the target nucleic acid probes and which further comprise a plurality of detectable moieties, such as haptens.
Ventana Medical Systems | Date: 2016-06-28
Systems and methods for speeding up a spectral unmixing process by using pixel groups are disclosed. Operations including forming groups of similar pixels, and unmixing only one representative pixel from each pixel group enable determination of an unmixing result for all the pixels in the group. A similarity metric may be based on a dot product of an unprocessed pixel with the representative pixel in the subset of pixels. The method is repeated for any number of remaining unmatched pixels that exceed a threshold, until the number of remaining or unmatched pixels is smaller than the threshold, upon which the remaining pixels may be individually unmixed. Significantly fewer unmixing operations are performed on an image, thereby speeding up the unmixing process.
Ventana Medical Systems and Stanford University | Date: 2016-12-09
The subject disclosure presents systems and computer-implemented methods for assessing a risk of cancer recurrence in a patient based on a holistic integration of large amounts of prognostic information for said patient into a single comparative prognostic dataset. A risk classification system may be trained using the large amounts of information from a cohort of training slides from several patients, along with survival data for said patients. For example, a machine-learning-based binary classifier in the risk classification system may be trained using a set of granular image features computed from a plurality of slides corresponding to several cancer patients whose survival information is known and input into the system. The trained classifier may be used to classify image features from one or more test patients into a low-risk or high-risk group.
Ventana Medical Systems | Date: 2017-03-22
The present invention relates to antibody-signal generating moiety conjugates, wherein the antibody is covalently linked to the signal generating moiety through a heterobifunctional polyethylene glycol (PEG) linker.
Ventana Medical Systems and University of Arizona | Date: 2016-08-19
The disclosure provides methods for characterizing a prostate cancer sample by detecting expression of ERG, PTEN or both, changes in which relative to a normal control are shown herein to be correlated with prostate cancer capsular penetration and more aggressive forms of prostate cancer. Such methods are useful for the prognosis of prostate cancer capsular penetration and for making treatment decisions in patients with prostate cancer that has penetrated the capsule. Also provided are kits that can be used with such methods.